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Abbreviations 
ASA American Society of Anesthesiologists 
BMI body mass index 
CI confidence interval 
CRP C-reactive protein 
CSS cancer specific survival 
F female 
FBC full blood count 
Hb haemoglobin 
HR hazard ratio 
IL interleukin 
LOD limit of detection 
M male 
MCH mean corpuscular haemoglobin 
MCV mean corpuscular volume 
mGPS modified Glasgow Prognostic Score 
NLR neutrophil lymphocyte ratio 
OS overall survival 
RDW red cell distribution width 
sTFR soluble transferrin receptor 
TIBC total iron binding capacity 
TSAT transferrin saturation,  
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Abstract 
 
Background: 
Inflammation is recognised to be associated with perturbation of serum measures of iron 
status.  However, the impact of colorectal cancer associated host inflammation on red cell 
measures of iron status has not been previously quantified.   
 
Methods: 
Patients undergoing elective surgery with curative intent, for colorectal cancer, at a single 
centre between 2008 and 2017 were included (n=824).  Blood samples taken for C-reactive 
protein (CRP), albumin, and full blood count (FBC) allowed patients to be grouped by 
modified Glasgow Prognostic Score (mGPS), and anaemia subtype (haemoglobin (Hb) 
M<130 mg/L and F<120 mg/L, with microcytic anaemia being mean corpuscular volume 
(MCV) <80 f/L, and normocytic anaemia with MCV 80-100 f/L).  Relationships between 
these groupings and red cell measures iron status including Hb, MCV, mean corpuscular 
haemoglobin (MCH) and red cell distribution width (RDW) were examined.   
 
Results: 
The combination of increasing T stage and increasing mGPS was associated with lower Hb, 
lower MCV, lower MCH, higher RDW, and higher prevalence of both microcytic and 
normocytic anaemia (all p<0.001).  The combination of CRP >10mg/L and albumin <35g/L 
was associated with lower Hb, lower MCV, lower MCH, higher RDW, and higher prevalence 
of both microcytic and normocytic anaemia (all p<0.010).  At multivariate Cox regression 
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only Hb remained significantly associated with cancer specific (HR 0.98, 95% CI 0.97-0.99, 
p<0.001), and overall survival (HR 0.98, 95% CI 0.97-0.99, p=0.001).   
 
Conclusions: 
The presence of a host systemic inflammatory response to colorectal cancer was associated 
with significant perturbation of red cell measure of iron status.   
 
  
5 
 
1.0 Introduction 
 
Long term outcome following diagnosis with colorectal cancer is primarily related to disease 
stage at presentation.  Although tumour factors remain key determinants of outcome, it is 
increasingly recognised that host factors also have a prognostic role [1].  In particular, the 
presence of an innate systemic inflammatory response prior to surgery is associated with 
poorer survival across a wide variety of solid tumours, including colorectal cancer [2].  The 
modified Glasgow Prognostic Score is a validated prognostic measure of the host systemic 
inflammatory response in colorectal cancer and other solid tumours [3]. 
At the time of diagnosis, around 30% of patients with colorectal cancer are found to be 
anaemic [4].  Whilst traditionally in colorectal cancer this has been thought to be mainly iron 
deficiency anaemia due to luminal blood loss, recent studies in fact suggest that normocytic 
anaemia, related to inflammation, is in fact more prevalent in this group of patients [5].  
Furthermore, such normocytic anaemia has been reported to be a further host factor 
associated with poorer prognosis, more so than the microcytic anaemia of iron deficiency [4-
5]. 
The presence of a systemic inflammatory response is recognised to significantly confound 
common measures of serum iron status including serum iron, transferrin saturation, and 
ferritin [6].  In addition, there are commonly measured parameters of the circulating 
erythrocyte population such as haemoglobin (Hb), mean corpuscular volume (MCV) mean 
corpuscular haemoglobin (MCH) and red cell distribution width (RDW) [7].  These variables 
may reflect iron status but are also recognised to be influenced by systemic inflammation [8]. 
The aim of the present study was to quantify the impact of the host systemic inflammatory 
response to colorectal cancer on these measures of the circulating erythrocyte population, 
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subtypes of anaemia, and survival in patients undergoing potentially curative treatment for 
colorectal cancer. 
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2.0 Patients and Methods 
 
2.1 Patients 
This study was a retrospective observational analysis of a prospectively collected and 
maintained database of patients undergoing potentially curative surgery for colorectal cancer 
at a single centre.  Patients undergoing elective surgery between January 2008 and June 2017 
for histologically confirmed colorectal cancer were included.  Patients undergoing emergency 
or palliative surgery, along with those with known existing inflammatory or haematological 
disorders were excluded.   
All patients were discussed at a specialist colorectal cancer multidisciplinary team meeting 
before and after surgery.  Tumours were staged according to the 5th edition of the TNM 
system [9]. 
This observational study was approved by the West of Scotland research ethics committee. 
 
2.2 Methods 
Haematological parameters were recorded from the electronic laboratory reporting systemic 
from Full Blood Count samples taken within the 2 weeks prior to surgery.  Patients were 
classified as having anaemia based on WHO guidelines for males; haemoglobin (Hb) <130 
mg/L and females; Hb <120 mg/L [10].  Furthermore, anaemic patients were classified as 
having microcytic anaemia with mean corpuscular volume (MCV) <80 f/L, normocytic 
anaemia with MCV 80-100 f/L, or macrocytic anaemia with MCV >100 f/L.   
Both the modified Glasgow Prognostic Score (mGPS) and the neutrophil to lymphocyte ratio 
(NLR) were used as markers of the preoperative SIR and were obtained from preoperative 
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blood results.  Serum concentrations of C-reactive protein (CRP) (mg/L) were measured 
using an autoanalyzer (Architect; Abbot Diagnostics, Maidenhead, UK) with a lower 
detectable limit of 0.2 mg/L as was serum albumin (normal range 35-50g/L).  The 
preoperative modified Glasgow Prognostic Score (mGPS: CRP ≤10 mg/L = 0. CRP > 10 
mg/L and albumin ≥35 g/L = 1, CRP >10 mg/L and albumin <35 g/L = 2), associated with 
cancer specific survival in multiple solid tumours, was calculated in patients for whom serum 
CRP and albumin concentrations were available [3]. 
 
2.3 Statistical Analysis 
The associations between anaemia subtypes and clinicopathological characteristics, between 
T stage, mGPS and measures of the circulating erythrocyte population, and between CRP, 
albumin and measures of the circulating erythrocyte population were examined using the chi 
square test and chi square test of linear association where appropriate. 
Deaths within 30 days of surgery or during the index admission were excluded from survival 
analysis.  Cancer specific survival (CSS) was defined as time from date of surgery to death 
due to colorectal cancer while overall survival (OS) was defined as time from date of surgery 
to death of any cause.  The association between measures of the circulating erythrocyte 
population, anaemia subtypes and survival were analysed using univariate Cox regression, 
and Kaplan Meier curves were used to examine the relationship between normocytic anaemia 
and survival in patients grouped by mGPS.  Multivariate Cox regression using a backward 
conditional model was then applied to those variables found to be associated with CSS or OS 
at a univariate level of p<0.1. 
All statistical analyses were performed using SPSS version 24 (IBM, IL, USA).  P values 
<0.05 were considered statistically significant. 
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3.0 Results 
 
3.1 Patients: 
Eleven patients were found to have macrocytic anaemia and due to the small numbers were 
excluded from analysis.  Therefore the study included 824 patients with colorectal cancer 
who underwent surgery with curative intent at a single centre during the study period (Table 
1).  Of these, the majority were male (55%), over 64 years old (65%), with colonic (63%) and 
node negative (63%) disease.  Of the included patients, 321 (39%) were anaemic at diagnosis, 
with 69 (8%) having microcytic anaemia and 252 (31%) having normocytic anaemia.  
 
3.2 Association between anaemia subtypes and clinicopathological variables: 
When compared to no anaemia and microcytic anaemia (Table 1), normocytic anaemia was 
associated with the highest proportion of negative host characteristics including patients >75 
years old (p<0.001), the highest proportion of patients with ASA grade 3 and 4 (p<0.001), the 
lowest proportion of patients with BMI >30 kg/m2 (p=0.001), and the highest proportion of 
patients with mGPS 2 (p<0.001).  However, microcytic anaemia was associated with the 
highest proportion of negative tumour characteristics including the highest proportion of T 
stage 4 (p<0.001) and poor differentiation (p=0.004).  Those without anaemia had the highest 
proportion of rectal cancers (p<0.001). 
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3.3 Association between T stage, mGPS and measures of the circulating erythrocyte 
population: 
There were statistically significant associations (Table 2) between median Hb, MCV, MCH, 
RDW, and both T stage and mGPS. In general, those patients with a higher T stage, and 
higher mGPS had lower Hb (p<0.001), lower MCV (p<0.001), lower MCH (p<0.001) and 
higher RDW (p<0.001).  A significantly greater proportion of patients with higher T stage 
and higher mGPS were found to have either normocytic anaemia (p<0.001), or microcytic 
anaemia (p<0.001). 
 
3.4 Association between CRP, albumin and measures of the circulating erythrocyte 
population: 
There were statistically significant associations (Table 3) between median Hb, MCV, MCH, 
RDW and both CRP and albumin.  In general, those patients with a higher CRP and lower 
albumin (i.e. greater inflammation), had lower Hb, (p<0.001), lower MCV (p=0.001), lower 
MCH (p<0.001), and higher RDW (p<0.001).  A significantly greater proportion of patients 
with higher CRP and lower albumin were found to have either normocytic anaemia 
(p<0.001), or microcytic anaemia (p=0.004). 
 
3.5 Association between measures of the circulating erythrocyte population and survival: 
There were 12 deaths in the perioperative period, excluded from survival analysis.  Long term 
survival data was available for 782 patients.  There were 181 deaths (23%), of which 104 
(13%) were due to colorectal cancer.  The median length of follow up amongst those patients 
alive at the time of follow up was 52 months (range 12-122). 
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At univariate analysis (Table 4) preoperative Hb (HR 0.98, 95% CI 0.97-0.99, p<0.001) and 
normocytic anaemia (HR 1.98, 95% CI 1.34-2.89, p<0.001) were associated with cancer 
specific survival.  When patients were grouped by inflammatory state (Figure 1) there was no 
significant association between normocytic anaemia and cancer specific survival in either 
patients with mGPS 0 (p=0.063) or mGPS 1-2 (p=0.086).     
At univariate analysis (Table 4) preoperative Hb (HR 0.98, 95% CI 0.97-0.99, p<0.001), 
MCH (HR 1.01, 95% CI 1.00-1.02, p=0.006), RDW (HR 1.07, 95% CI 1.02-1.13, p=0.006), 
and normocytic anaemia (HR 1.94, 95% CI 1.45-2.60, p<0.001) were associated with overall 
survival.  When patients were grouped by inflammatory state (Figure 2) normocytic anaemia 
was associated with significantly poorer overall survival in both patients with mGPS 0 
(p=0.046) and mGPS 1-2 (p<0.001).     
When those haematological factors which were significantly associated with cancer specific 
survival (Hb) and overall survival (Hb, MCH and normocytic anaemia) at univariate analysis 
were included in multivariate analysis along with established prognostic factors such as age, 
sex, ASA grade, tumour location, mGPS, TNM stage, differentiation (Table 5), none retained 
independent prognostic significance. 
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4.0 Discussion 
 
The results of the present study report a significant association between T stage, the presence 
a host systemic inflammatory response, and red cell markers of iron status in patients with 
colorectal cancer.  In addition, an increasing magnitude of innate systemic inflammation 
appears to be associated with progressive derangement of these measures.  Furthermore, the 
presence of anaemia, and particularly normocytic anaemia, was associated with poorer cancer 
specific and overall survival independent of systemic inflammation in this cohort of patients. 
These results are in keeping with recently published results from our own group [4], and 
others [5], which reported an association between systemic inflammation and anaemia in 
patients with colorectal cancer.  It is well understood that the presence of systemic 
inflammation of any cause leads to significant derangement of common serum measures of 
iron status; including total iron, transferrin saturation, and ferritin [6].  This is thought to 
occur due to the action of hepcidin, upregulated by the proinflammatory cytokine IL 6, 
resulting in inhibition of enteric iron absorption and sequestration of iron and ferritin in the 
liver and reticuloendothelial system [11].  Indeed, this effect has in part lead to the search for 
novel measures of iron status which are not affected in such a way, and in other attempts to 
formulate correction factors and equations to account for inflammation when using these 
measures of iron status [12-13]. 
Inflammation is recognised to lead to anaemia through three broad mechanisms, the first 
being the inflammation related hypoferraemia, or functional iron deficiency, driven by 
hepcidin described above [11].  In addition, proinflammatory cytokines tend to have a 
suppressive effect on erythropoiesis through their inhibitory relationship with erythroid 
precursors [14].  Finally, activated macrophages reduce the life span of circulating red cells 
through enhanced phagocytosis [15].  In colorectal cancer, anaemia has traditionally been 
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attributed to frank or occult gastrointestinal blood loss.  However, when the results of the 
present study are taken together with other recently published cohorts, it would appear that 
anaemia of inflammation is in fact far more prevalent in this group of patients than has been 
previously recognised [4-5].   
The presence of host systemic innate inflammatory responses to colorectal cancer, and their 
negative prognostic impact, are well documented [16].  The presence of anaemia has also 
long been recognised to be associated with poorer outcomes [17].  Therefore, the increasing 
evidence of association between cancer related inflammation, and normocytic anaemia in 
particular, is of great significance [5].  Inflammation associated normocytic anaemia has been 
reported to be associated with poorer outcomes than classical microcytic anaemia of blood 
loss in several cohorts [4].  Unlike the previous studies [4-5, 8], multivariate survival analysis 
in the present cohort did not find normocytic anaemia to be independently prognostic.  This is 
possibly due to the significant co-dependent relationship between Hb and normocytic 
anaemia, and the fact that a continuous variable was compared to a binary categorical 
variable.   Alternatively, it may reflect the importance of the underlying host systemic 
inflammatory response as a mechanism underpinning anaemia, and disease progression.  
However, Figure 1 shows that a proportion of patients with mGPS 0 have normocytic 
anaemia, and that this still appears to impart a negative prognosis.  Either other factors lead to 
normocytic anaemia in these patients, or much lower levels of inflammation than those 
thresholds used to determine mGPS are having an effect.  The precise mechanisms linking 
these phenomena to poorer outcomes remain poorly understood. 
 
This area is of further interest to those involved in surgery and perioperative medicine in this 
group of patients.  This group of patients still require significant rates of perioperative blood 
transfusion, an intervention associated with significant cost, complications, and possibly a 
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negative oncologic impact [18].  There has been a drive to reduce perioperative blood 
transfusion rates in colorectal cancer patients using preoperative oral and parenteral iron 
replacement, with some initially encouraging results [19].  However, the large group of 
patients with normocytic anaemia of inflammation have never been considered in their own 
right [20].  Given the possibility that systemic inflammation will prevent the efficient 
utilisation of administered supplemental iron, this should form an important area of future 
research.   
The present study has several limitations. The retrospective nature of the study means that not 
all patients had CRP and albumin recorded along with the red cell measures of iron status, 
leading to loss of data, especially in later analyses.  Data were not immediately available 
regarding perioperative blood transfusion, a factor thought to relate to oncologic outcome. 
Furthermore, insufficient data regarding serum measures of iron status, such as ferritin or 
transferrin saturation, were collected to allow meaningful correlation between those and red 
cell measures of iron status. It should be noted that around 200 patients from the single centre 
within the present study are included in our previous published bowel screening cohort [4], 
however that cohort as a whole did not have measures of red cell iron status other than Hb 
and MCV available.  Finally, the patients in the present paper were stages using the older 
TNM 5th edition.  Using the more current 7th edition might result in an upstaging from node 
negative to node positive disease in less than 3% of cases so would hopefully have little 
impact on the results [21].  Another factor reducing this possible bias is that in the present 
study there was no association between N stage and preoperative anaemia. 
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5.0 Conclusions 
In summary, the results of the present study report that the presence of a host systemic 
inflammatory response to colorectal cancer is associated with significant perturbation of red 
cell measures of iron status.  Furthermore, the results from this cohort add to the existing 
evidence reporting the high prevalence of preoperative normocytic anaemia in this patient 
group, its association with systemic inflammation, and poorer cancer outcomes.  Future 
investigation should aim to determine whether existing perioperative iron and blood 
management strategies are of use in this subgroup. 
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Tables and footnotes 
Table 1: Clinicopathological characteristics of patients undergoing elective surgery for 
colorectal cancer grouped by preoperative anaemia 
Anaemia£ None  
 n (%) 
Microcytic$  
n (%) 
Normocytic*  
n (%) 
p 
 
 
N 503 (61) 69 (8) 252 (31)  
Demographic     
Sex     
Male 263 (53) 42 (61) 150 (60) 0.118 
Female 238 (47) 27 (39) 102 (40)  
Age     
<65 202 (40) 27 (39) 58 (23) <0.001 
64-74 212 (42) 22 (32) 90 (36)  
>75 89 (18) 20 (29) 104 (41)  
ASA     
1 128 (26) 11 (16) 30 (13) <0.001 
2 227 (46) 28 (42) 106 (44)  
3 127 (26) 24 (36) 91 (38)  
4 7 (1) 4 (6) 13 (5)  
BMI 
<20 
20-25 
25-30 
    
0.001 19 (4) 8 (13) 24 (10) 
154 (32) 20 (32) 83 (34) 
146 (30) 17 (27) 82 (34) 
>30 162 (34) 17 (27) 52 (22)  
Smoking status     
Never 
Ex 
Current 
240 (49) 32 (49) 117 (47) 0.099 
177 (36) 27 (41) 108 (44) 
74 (15) 7 (10) 22 (9)  
Neoadjuvant treatment     
Yes 83 (17) 4 (6) 38 (15) 0.069 
No 415 (83) 64 (94) 210 (85)  
Pathological     
Tumour site     
Colon 269 (54) 62 (90) 187 (75) <0.001 
Rectum 234 (47) 7 (10) 64 (25)  
T stage     
0/1 101 (20) 3 (5) 16 (7) <0.001 
2 93 (19) 2 (3) 23 (9)  
3 236 (47) 39 (58) 157 (63)  
4 69 (14) 23 (34) 53 (21)  
N stage     
0 327 (66) 36 (54) 154 (62) 0.408 
1 121 (24) 22 (33) 66 (27)  
2 59 (10) 9 (13) 28 (11)  
Differentiation     
Well / Mod 453 (93) 54 (82) 221 (90) 0.004 
Poor 27 (7) 12 (18) 23 (10)  
Venous invasion     
Present 286 (58) 44 (67) 148 (59) 0.381 
Absent 209 (42) 22 (33) 101 (41)  
Systemic inflammation     
NLR     
≥5 57 (12) 9 (14) 41 (17) 0.143 
<5 438 (88) 57 (86) 204 (83)  
mGPS     
0 401 (85) 43 (72) 163 (72) <0.001 
1 48 (10) 5 (8) 15 (7)  
2 21 (5) 12 (20) 48 (21)  
21 
 
ASA American Society of Anesthesiology, BMI body mass index, mGPS modified Glasgow Prognostic Score, 
NLR neutrophil-to-lymphocyte ratio 
£Males = Hb <130g/L, females <120g/L 
$Anaemia and MCV <80fL 
*Anaemia and MCV 80-100fL 
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Table 2: Relationship between T stage, systemic inflammation and haematological 
parameters in 
Number of patients, n     
 T stage  
 All 0-2 3-4  
mGPS     
All 748 225 523  
0 601 202 399  
1-2 147 23 124  
     
Haemoglobin, median, range 
(mg/L) 
    
 T stage p 
 All 0-2 3-4  
mGPS     
All 130 (63 – 194) 137 (94 – 172) 125 (63 – 194) <0.001 
0 132 (81-194) 138 (94 – 172) 129 (81 – 194) <0.001 
1-2 123 (74– 162) 130 (108 – 154) 120 (74 – 162) <0.001 
p <0.001 0.070 <0.001 <0.001 
     
MCV, median, range (fL)     
 T stage p 
 All 0-2 3-4  
mGPS     
All 89 (64 – 105) 91 (69 – 104) 89 (64 – 105) <0.001 
0 90 (68 – 105)  91 (69 – 104) 89 (68 – 105)  <0.001 
1-2 87 (64 – 103) 90 (80 – 100) 87 (64 – 103) <0.001 
p <0.001 0.483 0.001 <0.001 
     
MCH, median, range (g/dL)     
 T stage p 
 All 0-2 3-4  
mGPS     
All 29.4 (18.0 – 46.7) 30.2 (20.6 – 36.4) 29.1 (18.0 – 46.7) <0.001 
0 29.7 (19.2 – 36.4) 30.2 (20.6 – 36.4) 29.4 (19.2 – 35.7) <0.001 
1-2 28.0 (18.0 – 35.4) 29.2 (24.8 – 35.2) 27.8 (18.0 – 35.4) 0.009 
p <0.001 0.173 <0.001 <0.001 
     
RDW, median, range (%)     
 T stage p 
 All 0-2 3-4  
mGPS     
All 14.0 (11.7 – 27.1) 13.5 (11.8 – 24.2) 14.3 (11.7 – 27.1) <0.001 
0 13.8 (11.7 – 27.1) 13.5 (11.8 – 24.2) 14.1 (11.7 – 27.1) <0.001 
1-2 14.9 (12.1 – 23.8) 13.8 (12.1 – 15.9) 15.1 (12.3 – 23.8) 0.015 
p 0.002 0.801 0.013 <0.001 
     
Microcytic$ anaemia£, n (%)     
 T stage p 
 All 0-2 3-4  
mGPS     
All 59 (8) 5 (2) 54 (10) <0.001 
0 42 (7) 5 (3) 37 (9) 0.002 
1-2 17 (11) 0 (0) 17 (13) 0.057 
p 0.075 0.436 0.166 <0.001 
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Normocytic* anaemia£, n 
(%) 
    
 T stage p 
 All 0-2 3-4  
mGPS     
All 223 (29) 36 (16) 187 (35) <0.001 
0 161 (27) 28 (14) 133 (33) <0.001 
1-2 62 (41) 8 (33) 54 (43) 0.401 
p <0.001 0.014 0.046 <0.001 
     
mGPS modified Glasgow Prognostic Score, MCV mean corpuscular volume, MCH mean corpuscular 
haemoglobin, RDW red cell distribution width 
£Males = Hb <130g/L, females <120g/L 
$Anaemia and MCV <80fL 
*Anaemia and MCV 80-100fL 
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 Table 3: Relationship between systemic inflammation as measured by C-reactive protein 
(mg/L) and albumin (g/L), and anaemia in patients undergoing elective surgery for colorectal 
cancer (n=615) 
Number of patients, n     
 CRP (mg/L)  
 All <10 >10  
Albumin (g/L)     
All 615 470 145  
>35 432 369 101  
<35   183 101 82  
     
Haemoglobin, median, range (mg/L)    
 CRP (mg/L) p 
 All <10 >10  
Albumin (g/L)     
All 130 (74 – 18.2) 132 (81 – 182) 122 (74 – 162) <0.001 
>35 135 (88 – 182) 135 (88 – 182) 132 (90 – 162) 0.190 
<35 118 (74 – 162) 125 (81 – 162) 111 (74 – 151) 0.001 
p <0.001 <0.001 <0.001 <0.001 
     
MCV, median, range (fL)     
 CRP (mg/L) p 
 All <10 >10  
Albumin (g/L)     
All 89 (64 – 105) 90 (68 – 105) 87 (64 – 103) <0.001 
>35 90 (68 – 105) 90 (68 – 105) 87 (71 – 103) 0.019 
<35 88 (64 – 103) 89 (70 – 102) 87 (64 – 103) 0.055 
p 0.029 0.355 0.387 0.001 
 
MCH, median, range (g/dL)     
 CRP (mg/L) p 
 All <10 >10  
Albumin (g/L)     
All 29.4 (18.0 – 36.4) 29.7 (19.2 – 36.4) 28.0 (18.0 – 35.4) <0.001 
>35 29.7 (19.2 – 36.4) 29.8 (19.2 – 36.4) 28.9 (21.9 – 35.4) 0.013 
<35 28.3 (18.0 – 35.7) 28.9 (19.3 – 35.7) 27.6 (18.0 – 35.2) 0.018 
p <0.001 0.003 0.015 <0.001 
 
RDW, median, range (%)     
 CRP (mg/L) p 
 All <10 >10  
Albumin (g/L)     
All 14.0 (11.8 – 27.1) 13.8 (11.8 – 27.1) 14.9 (12.1 – 23.8) 0.006 
>35 13.8 (11.8 – 27.1) 13.8 (11.8 – 27.1) 14.0 (12.1 – 23.3) 0.666 
<35 15.2 (12.6 – 24.8) 14.4 (12.8 – 24.8) 16.0 (12.6 – 23.8) 0.011 
p <0.001 0.048 0.001 <0.001 
     
Microcytic$ anaemia£, n (%)     
 CRP (mg/L) p 
 All <10 >10  
Albumin (g/L)     
All 46 (8) 30 (6) 16 (11) 0.063 
>35 25 (6) 21 (6) 4 (6) 0.852 
<35 21 (12) 9 (9) 12 (15) 0.234 
p 0.011 0.215 0.102 0.004 
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Normocytic* anaemia£, n (%)    
 CRP (mg/L) p 
 All <10 >10  
Albumin (g/L)     
All 191 (31) 128 (27) 63 (43) <0.001 
>35 97 (22) 82 (22) 15 (23) 0.813 
<35 94 (52) 46 (47) 48 (59) 0.087 
p <0.001 <0.001 <0.001 <0.001 
     
MCV - mean corpuscular volume, MCH - mean corpuscular haemoglobin, RDW - red blood cell distribution 
width, CRP - C-reactive protein 
£Males = Hb <130g/L, females <120g/L,  
$Anaemia and MCV <80fL,  
*Anaemia and MCV 80-100fL 
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Table 4: Univariate and multivariate survival analysis of haematological parameters in 
patients with colorectal cancer treated with curative intent 
Variable Univariate survival Multivariate survival 
HR (95% CI) p HR (95% CI) p 
CSS     
Haemoglobin (mg/L) 0.98 (0.97-0.99) <0.001 0.98 (0.97-0.99) <0.001 
MCV (fL) 1.00 (0.98-1.03) 0.859 - - 
MCH (g/dL) 0.98 (0.92-1.04) 0.402 - - 
RDW (%) 1.06 (0.99-1.14) 0.111 - - 
Microcytic$ anaemia£ 1.27 (0.68-2.37) 0.458 - - 
Normocytic* anaemia£ 1.98 (1.34-2.89) <0.001 - 0.152 
OS     
Haemoglobin (mg/L) 0.98 (0.97-0.99) <0.001 0.98 (0.97-0.99) 0.001 
MCV (fL) 1.00 (0.98-1.02) 0.879 - - 
MCH (g/dL) 1.01 (1.00-1.02) 0.006 1.01 (1.01-1.02) <0.001 
RDW (%) 1.07 (1.02-1.13) 0.008 - 0.383 
Microcytic$ anaemia£ 1.20 (0.74-1.95) 0.461 - - 
Normocytic* anaemia£ 1.94 (1.45-2.60) <0.001 1.43 (0.97-2.12) 0.069 
MCV - mean corpuscular volume, MCH - mean corpuscular haemoglobin, RDW - red blood cell distribution 
width, CRP - C-reactive protein 
£Males = Hb <130g/L, females <120g/L,  
$Anaemia and MCV <80fL,  
*Anaemia and MCV 80-100fL 
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Table 5: Univariate and multivariate survival analysis comparing haematological parameters 
to established prognostic factors 
Survival Variable Univariate HR 
(95% CI) 
P Multivariate HR 
(95% CI) 
P 
CSS Age 1.52 (1.19-1.94) 0.001 1.38 (1.06-1.81) 0.018 
 Male Sex 1.24 (0.85-1.82) 0.264 - - 
 ASA 1.38 (1.08-1.75) 0.010 - 0.394 
 mGPS 1.61 (1.25-2.08) <0.001 1.37 (1.06-1.78) 0.017 
 Rectal 0.92 (0.62-1.35) 0.649 - - 
 Differentiation 2.34 (1.40-3.93) 0.001 2.40 (1.36-4.22) 0.002 
 Venous invasion 1.83 (1.22-2.75) 0.004 - 0.869 
 TNM stage 2.46 (1.91-3.18) <0.001 2.42 (1.83-3.20) <0.001 
 Haemoglobin (g/L) 0.98 (0.97-0.99) <0.001 - 0.342 
 Adjuvant treatment 1.03 (0.68-1.56) 0.899 - - 
OS Age 1.77 (1.47-2.14) <0.001 1.58 (1.27-1.96) <0.001 
 Male Sex 1.38 (1.03-1.85) 0.029 1.33 (0.97-1.83) 0.081 
 ASA 1.63 (1.36-1.96) <0.001 1.34 (1.09-1.65) 0.006 
 mGPS 1.78 (1.48-2.14) <0.001 1.54 (1.27-1.87) <0.001 
 Rectal 0.82 (0.61-1.10) 0.182 - - 
 Differentiation 1.95 (1.28-2.97) 0.002 1.79 (1.09-2.94) 0.022 
 Venous invasion 1.41 (1.05-1.89) 0.021 - 1.000 
 TNM stage 1.75 (1.46-2.09) <0.001 1.72 (1.40-2.11) <0.001 
 Haemoglobin (g/L) 0.98 (0.97-0.99) <0.001 - 0.294 
 MCH (g/dL) 1.01 (1.00-1.02) 0.006 - 0.125 
 Normocytic* anaemia£ 1.94 (1.45-2.60) 0.001 - 0.266 
 Adjuvant treatment 0.78 (0.56-1.08) 0.138 - - 
ASA American Society of Anesthesiology, HR Hazard Ratio, CI Confidence Interval , CSS  disease specific 
survival, OS overall survival, mGPS modified Glasgow Prognostic Score, POD postoperative day MCH mean 
corpuscular haemoglobin 
£Males = Hb <130g/L, females <120g/L,  
$Anaemia and MCV <80fL,  
*Anaemia and MCV 80-100fL 
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Figures and Legends 
 
Figure 1: Kaplan Meier charts of (A) cancer specific survival amongst patients with modified 
Glasgow Prognostic Score 0 (p=0.063), (B) cancer specific survival amongst patients with 
modified Glasgow Prognostic Score 1-2 (p=0.086), (C) overall survival amongst patients 
with modified Glasgow Prognostic Score 0 (p=0.046), and (D) overall survival amongst 
patients with modified Glasgow Prognostic Score 1-2 (p<0.001), grouped by preoperative 
normocytic anaemia 
 
 
 
